Viking Therapeutics (VKTX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is VKTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Dosing flexibility across weekly, biweekly, and monthly schedules gives Viking a structural advantage that currently approved competitors don't yet offer.…

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15…

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.…

Viking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share. Peak sales and valuation projections need to be based on risk-adjusted scenarios.…

Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company, is also looking to m…

Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.…

Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SA…

Viking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.…

The weight loss drug market is on track to reach nearly $100 billion by the end of the decade. Viking has a candidate, in two formulations, involved in phase 3 studies.…

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders,…

UBS sees approximately 250% upside potential for Viking shares over the next year. Viking's weight loss candidates could compete effectively with the established drugs from Eli Lilly and Novo Nordisk.…

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.…

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's …

Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for injectable VK2735, and SUNRIS…

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.…

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.…

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1…

Viking Therapeutics' maintenance data met upside criteria but failed to excite the market, with shares dropping post-release and dilution ongoing. VKTX is clearly pursuing a standalone strategy, ramping OpEx and infrastr…

Viking Therapeutics NASDAQ: VKTX reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of its lead candidate, …

Viking Therapeutics, Inc. (VKTX) Q3 2026 Earnings Call Transcript…

-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Pa…

VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.…

Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company foc…

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biop…

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Vik…

Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel thera…

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary du…

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today an…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

